Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

ClinicalTrials.gov ID: NCT04564339

Public ClinicalTrials.gov record NCT04564339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

Study identification

NCT ID: NCT04564339
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 123 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 19, 2021 (Actual)
Primary completion: Mar 26, 2025 (Actual)
Completion: Aug 18, 2025 (Actual)
Last update posted: Jan 22, 2026

2021 – 2025

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research Site	San Dimas	California	91773	—
Research Site	Santa Monica	California	90404	—
Research Site	South Gate	California	90280	—
Research Site	Stanford	California	94305	—
Research Site	Orlando	Florida	32835	—
Research Site	Plantation	Florida	33324	—
Research Site	Lawrenceville	Georgia	30046	—
Research Site	Lexington	Kentucky	40536	—
Research Site	Louisville	Kentucky	40202	—
Research Site	Boston	Massachusetts	02114	—
Research Site	Boston	Massachusetts	02115	—
Research Site	Kansas City	Missouri	64111	—
Research Site	New York	New York	10003	—
Research Site	Chapel Hill	North Carolina	27599	—
Research Site	Columbus	Ohio	43203	—
Research Site	El Paso	Texas	79935	—
Research Site	Houston	Texas	77054	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04564339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 22, 2026 · Synced Nov 5, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04564339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →